We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases

By LabMedica International staff writers
Posted on 04 Mar 2024
Print article
Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)
Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)

The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting urine over several days. However, this method requires great perseverance from patients, as collecting every drop of urine over several days can be nearly impossible, even if the patients are hospitalized. This often leads to up to 60% variation in urine-free cortisol measurements in individual patients. Now, researchers have developed a new method for measuring cortisol levels directly from a blood sample, marking a significant advancement in the diagnosis and treatment of various diseases.

Researchers from Aarhus University (Aarhus, Denmark) have discovered a groundbreaking method for measuring levels of free cortisol directly from a blood sample. This new method is simple and quick, requiring only a few drops of blood. This contrasts sharply with current practices, which are both cumbersome and inaccurate. Traditional tests, for instance, cannot differentiate between synthetic and natural cortisol. This limitation is problematic in patients who have been treated with synthetic cortisol, as it can lead to misdiagnoses or incorrect medication dosages. The new method addresses these issues by employing a cell-based assay, which not only improves the accuracy and reliability of cortisol measurements but also reduces the high variation commonly seen in patient samples

An assay is an analytical procedure used to measure a substance's level, in this case, cortisol. The most common method currently is immunoassays using antibodies. However, the new method uses the cell-based assay HEK293F-GRE, which allows for the measurement of the total level of cortisol, including both natural free cortisol and synthetic cortisol from medicinal products. This new test has the potential to be a game-changer for diagnosing and treating patients who require cortisol regulation. This includes individuals with stress-related illnesses like anxiety and depression, chronic diseases such as diabetes and cancer, and inflammatory diseases like allergies and asthma. While there is still a need to explore how to best integrate this method into clinical practice, the goal is to make the test available using a standard blood sample for doctors, thereby improving patient care.

"Being able to measure the total cortisol level accurately means we can potentially adapt treatment more precisely and reduce the risk of side effects," said Andreas Lodberg, MD and postdoc at the Department of Biomedicine, Aarhus University. "Our validation shows that this method meets the stringent criteria set by the U.S. Food and Drug Administration, making it a promising candidate for future use in clinical laboratories."

Related Links:
Aarhus University 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.